How ABBV Stock Moved Away From Its Peer Group

AbbVie (ABBV) has shown strong fundamental performance with high revenue growth and operating margins, yet its stock returns significantly lag behind peers like Merck and Johnson & Johnson. This disconnect is attributed to the market pricing in future competitive threats to AbbVie's key drug franchises, despite management's efforts to build new growth platforms, particularly in its neuroscience division with an upcoming Parkinson's drug. Investors are looking to the success of these new ventures to determine if the stock price will eventually reflect the company's strong operational metrics.